The fight for our genes heads to court
By Editorial,
San Francisco Chronicle [cites Marcy Darnovksy]
| 05. 23. 2009
Twenty percent of your body belongs to someone else.
Don't believe us? Check the U.S. Patent Office. Twenty percent of all human genes have been patented, mostly by private companies and research institutions. These patents are crippling the ability of scientists to study diseases and restricting patients from getting the information they need to make important medical decisions about their health.
This month, six breast cancer patients filed suit against Myriad Genetics, a company that owns both the patent on two genes that are associated with an increased risk for breast cancer and ovarian cancer and the patent on testing to measure those risks. Some of these women are suing because they can't afford the $3,000 fee Myriad charges to determine their risk for breast or ovarian cancer. Some of them are suing because, thanks to Myriad's patent, they can't get second opinions about whether they should have their breasts or ovaries removed - no one else is allowed to perform another test for them.
All of them are suing because they did not, and should not, expect to have...
Related Articles
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...